Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer

Molecular Cancer Therapeutics

Volumn 12, Issue 3, 2013, Pages 295-305

  Damiano, Jason S ^a   Rendah, Katherine G ^a   Karim, Christopher ^a   Embry, Millicent G ^a   Ghoddusi, Majid ^a   Holash, Jocelyn ^a   Fanidi, Abdallah ^a   Abrams, Tinya J ^a   Abraham, Judith A ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LETROZOLE; MONOCLONAL ANTIBODY LFA102; NEUTRALIZING ANTIBODY; PROLACTIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER MODEL; CANCER REGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; EXTRACELLULAR SPACE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; MCF-7 CELLS; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROLACTIN; RATS; RECEPTORS, PROLACTIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874919434     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0886     Document Type: Article

References (48)

1. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007;25: 1482-8.
2. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, et al. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 2002;59: 1147-54.
3. Rose-Hellekant TA, Arendt LM, Schroeder MD, Gilchrist K, Sandgren EP, Schuler LA. Prolactin induces ERalpha-positive and ERalphanegative mammary cancer in transgenic mice. Oncogene 2003;22: 4664-74.
4. Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res 2011;13:R11.
5. Touraine P, Martini JF, Zafrani B, Durand JC, Labaille F, Malet C, et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J Clin Endocrinol Metab 1998;83: 667-74.
6. Xu J, Zhang Y, Berry PA, Jiang J, Lobie PE, Langenheim JF, et al. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol Endocrinol 2011;25: 597-610.
7. Longhi SA, Blank VC, Roguin LP, Cristodero M, Retegui LA. Relative localization of the prolactin receptor binding sites for lactogenic hormones. Growth Horm IGF Res 2001;11: 324-8.
8. Acosta JJ, Munoz RM, Gonzalez L, Subtil-Rodriguez A, Dominguez- Caceres MA, Garcia-Martinez JM, et al. Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Mol Endocrinol 2003;17: 2268-82.
9. Aksamitiene E, Achanta S, Kolch W, Kholodenko BN, Hoek JB, Kiyatkin A. Prolactin-stimulated activation of ERK1/2 mitogen-activated protein kinases is controlled by PI3-kinase/Rac/PAK signaling pathway in breast cancer cells. Cell Signal 2011;23: 1794-805.
10. Sakamoto K, Creamer BA, Triplett AA, Wagner KU. The Janus kinase 2 is required for expression and nuclear accumulation of cyclin D1 in proliferating mammary epithelial cells. Mol Endocrinol 2007;21: 1877-92.
11. Carver KC, Piazza TM, Schuler LA. Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells. J Biol Chem 2010;285: 8003-12.
12. Carver KC, Schuler LA. Prolactin does not require insulin-like growth factor intermediates but synergizes with insulin-like growth factor I in human breast cancer cells. Mol Cancer Res 2008;6: 634-43.
13. Huang Y, Li X, Jiang J, Frank SJ. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene 2006;25: 7565-76.
14. Ben-Jonathan N, Chen S, Dunckley JA, LaPensee C, Kansra S. Estrogen receptor-alpha mediates the epidermal growth factor-stimulated prolactin expression and release in lactotrophs. Endocrinology 2009;150: 795-802.
15. Yamauchi T, Yamauchi N, Ueki K, Sugiyama T, Waki H, Miki H, et al. Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. J Biol Chem 2000;275: 33937-44.
16. Fritze D, Queisser W, Schmid H, Kaufmann M, Massner B, Westerhausen M, et al. Prospective randomized trial concerning hyper- and normoprolactinemia and the use of bromoergocryptine in patients with metastatic breast cancer. Onkologie 1986;9: 305-12.
17. Holtkamp W, Nagel GA. [Bromocriptine in chemotherapy-resistant, metastatic breast cancer. Results of the GO-MC-BROMO 2/82 AIO Study]. Onkologie 1988;11: 121-7.
18. Ben-Jonathan N, Liby K, McFarland M, Zinger M. Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 2002;13: 245-50.
19. Clevenger CV, Plank TL. Prolactin as an autocrine/paracrine factor in breast tissue. J Mammary Gland Biol Neoplasia 1997;2: 59-68.
20. Hugo ER, Borcherding DC, Gersin KS, Loftus J, Ben-Jonathan N. Prolactin release by adipose explants, primary adipocytes, and LS14 adipocytes. J Clin Endocrinol Metab 2008;93: 4006-12.
21. Milewicz T, Rys J, Wojtowicz A, Stochmal E, Jach R, Krzysiek J, et al. Overexpression of P53 protein and local hGH, IGF-I, IGFBP-3, IGFBP- 2 and PRL secretion by human breast cancer explants. Neuro Endocrinol Lett 2011;32: 328-33.
22. Wu ZS, Yang K, Wan Y, Qian PX, Perry JK, Chiesa J, et al. Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma. J Clin Endocrinol Metab 2011;96:E1619-29.
23. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, et al. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 2004;64: 4774-82.
24. Bernichtein S, Kinet S, Jeay S, Llovera M, Madern D, Martial JA, et al. S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist. Endocrinology 2001;142: 3950-63.
25. Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005;26: 400-22.
26. Chen TJ,KuoCB, TsaiKF, LiuJW,ChenDY,WalkerAM.Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology 1998;139: 609-16.
27. Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res 1999;5: 3583-93.
28. Clevenger CV, Zheng J, Jablonski EM, Galbaugh TL, Fang F. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics. J Mammary Gland Biol Neoplasia 2008;13: 147-56.
29. Dagil R, Knudsen MJ, Olsen JG, O'Shea C, Franzmann M, Goffin V, et al. The WSXWS motif in cytokine receptors is a molecular switch involved in receptor activation: insight from structures of the prolactin receptor. Structure 2012;20: 270-82.
30. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24: 1-27.
31. van AJ, Zhang C, Tallet E, Raynal B, Hoos S, Baron B, et al. Structural characterization of the stem-stem dimerization interface between prolactin receptor chains complexed with the natural hormone. J Mol Biol 2010;404: 112-26.
32. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14: 737-44.
33. Binart N, Helloco C, Ormandy CJ, Barra J, Clement-Lacroix P, Baran N, et al. Rescue of preimplantatory egg development and embryo implantation in prolactin receptor-deficient mice after progesterone administration. Endocrinology 2000;141: 2691-7.
34. Perry JK, Mohankumar KM, Emerald BS, Mertani HC, Lobie PE. The contribution of growth hormone to mammary neoplasia. J Mammary Gland Biol Neoplasia 2008;13: 131-45.
35. Zuckier LS, Georgescu L, Chang CJ, Scharff MD, Morrison SL. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer 1994;73 Suppl: 794-9.
36. Smirnova OV, Petraschuk OM, Kelly PA. Immunocytochemical localization of prolactin receptors in rat liver cells: I. Dependence on sex and sex steroids. Mol Cell Endocrinol 1994;105: 77-81.
37. Biswas R, Vonderhaar BK. Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture. Cancer Res 1987;47: 3509-14.
38. Utama FE, Tran TH, Ryder A, LeBaron MJ, Parlow AF, Rui H. Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology 2009;150: 1782-90.
39. Utama FE, LeBaron MJ, Neilson LM, Sultan AS, Parlow AF, Wagner KU, et al.Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. J Endocrinol 2006;188: 589-601.
40. Schieweck K, Bhatnagar AS, Batzl C, Lang M. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen- dependent rat mammary tumors. J Steroid Biochem Mol Biol 1993;44: 633-6.
41. Dukes M. The relevance of preclinical models to the treatment of postmenopausal breast cancer. Oncology 1997;54 Suppl 2: 6-10.
42. Chen NY, Holle L, Li W, Peirce SK, Beck MT, Chen WY. In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRLG129R. Int J Oncol 2002;20: 813-8.
43. Schroeder MD, Brockman JL, Walker AM, Schuler LA. Inhibition of prolactin (PRL)-induced proliferative signals in breast cancer cells by a molecular mimic of phosphorylated PRL, S179D-PRL. Endocrinology 2003;144: 5300-7.
44. Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima G, et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 1996;271: 21969-77.
45. Rouet V, Bogorad RL, Kayser C, Kessal K, Genestie C, Bardier A, et al. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc Natl Acad Sci U S A 2010;107: 15199-204.
46. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 2007;67: 11991-9.
47. Bibeau F, Lopez-Crapez E, Di FF, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27: 1122-9.
48. Ormandy CJ, Camus A, Barra J, Damotte D, Lucas B, Buteau H, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 1997;11: 167-78.